Abstract
Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
Keywords: Radiation, heart, animal models, transforming growth factor-beta, renin-angiotensin system, mast cells, endothelin system, sensory nerves, models, transforming, angiotensin, endothelin, sensory, (RIHD), atherosclerosis, pericardial, myocardial fibrosis, pathogenesis, (myocardial necrosis, (PET), (SPECT), (RAS), Endothelial dysfunction, chemokines, TGF-β, mRNA, (Ang II), ACE, Captopril, (Ws), (CGRP), (TNF-α), IGF-1, (MMP), ETA, ETB
Current Drug Targets
Title: Potential Targets for Intervention in Radiation-Induced Heart Disease
Volume: 11 Issue: 11
Author(s): M. Boerma and M. Hauer-Jensen
Affiliation:
Keywords: Radiation, heart, animal models, transforming growth factor-beta, renin-angiotensin system, mast cells, endothelin system, sensory nerves, models, transforming, angiotensin, endothelin, sensory, (RIHD), atherosclerosis, pericardial, myocardial fibrosis, pathogenesis, (myocardial necrosis, (PET), (SPECT), (RAS), Endothelial dysfunction, chemokines, TGF-β, mRNA, (Ang II), ACE, Captopril, (Ws), (CGRP), (TNF-α), IGF-1, (MMP), ETA, ETB
Abstract: Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
Export Options
About this article
Cite this article as:
Boerma M. and Hauer-Jensen M., Potential Targets for Intervention in Radiation-Induced Heart Disease, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011405
DOI https://dx.doi.org/10.2174/1389450111009011405 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Expression and Role of the Calcium-Sensing Receptor in the Blood Vessel Wall
Current Pharmaceutical Biotechnology Anti-Thrombotic Properties of Tomato
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Depression and Vascular Disease: Conceptual Issues, Relationships and Clinical Implications
Vascular Disease Prevention (Discontinued) Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Lifestyle, Maternal Nutrition and Healthy Pregnancy
Current Vascular Pharmacology Value of Real Time Three Dimensional Transesophageal Echocardiography in General Cardiology Practice
Recent Patents on Medical Imaging Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Hypertension and Concurrent Arrhythmias
Current Pharmaceutical Design Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Analysis of the Selected Biochemical Blood Parameters in Patients After Total Hip Replacement
Current Rheumatology Reviews PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design The Role of Mineralocorticoid Receptor Antagonists in the Management of Heart Failure with Preserved Ejection Fraction
Current Pharmaceutical Design Establishing Genomic/Transcriptomic Links Between Alzheimer’s Disease and Type 2 Diabetes Mellitus by Meta-Analysis Approach
CNS & Neurological Disorders - Drug Targets PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol
Mini-Reviews in Medicinal Chemistry The Stress-Vulnerability Model of Schizophrenia: A Conceptual Analysis and Selective Review
Current Psychiatry Reviews Editorial (Thematic Issue: Sex, Environment, Physical Activity, Diet, and Obesity in Cardiovascular Disease Risk)
Current Vascular Pharmacology